An observational study in Neuromuscular Diseases in Infants and Neuromuscular Diseases in Children, sponsored by University Hospital, Tours. Completed at 1 site in France. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-12-09.
Sponsored by University Hospital, Tours · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies in Neuromuscular Diseases with a site in France — 14 open to participants now, 17 under way, 2 of them phase 3. Neuromuscular Diseases · France.
Among the 84 studies in Neuromuscular Diseases with a site in France, this one is the 24th largest by enrollment of the 36 observational ones that give a count, is one of 5 that started in 2018, is one of 36 observational ones, and was the 42nd registered.
361 studies on the registry are indexed under Neuromuscular Diseases; 97 are open to participants now.
Browse Neuromuscular Diseases studies →14 of the 84 studies in Neuromuscular Diseases with a site in France are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in France, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
Association APPROCHE · Sites in France
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 2+ · Healthy volunteers
University Hospital, Angers · Sites in France
Ages 6–17
AstraZeneca · Sites in France, United States, Canada and 7 more countries
Ages 18–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 70 Neuromuscular Diseases studies recruiting now, 39 (56%) set no upper age limit and 23 (33%) stop at 75 or younger; 36 take children under 18; 16 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 10
First in 2006; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 72 across 144 observational studies indexed under Neuromuscular Diseases.
Median enrollment 31 across the 48 interventional studies, 73 across the 36 observational. Of the 54 that completed or were terminated, 8 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 84 have an industry lead sponsor. The 10 most frequent:
University Hospital, Tours is the lead sponsor of 309 studies on the registry; 81 are open to participants now.
University Hospital, Tours has 1 study filed under Neuromuscular Diseases — fewer than ten, so there is no comparison to draw.
4 of the studies in Neuromuscular Diseases with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06249412Groupe Hospitalier du HavreThe Importance of Positive Expiratory Pressure Associated With the In-exsufflator in ALS Patients | 2026-12-01 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
| NCT07591779University Hospital, LimogesPhysical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment | 2027-04-15 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies in Neuromuscular Diseases with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Preliminary data underline the fact that muscular deoxygenation during training happens earlier in adult patients suffering from neuromuscular disorders in comparison to controls. Up to date, pediatric data are lacking.
The study aims at demonstrating if a correlation exists between the motor deficiency and the muscular deoxygenation in children suffering from neuromuscular disorders.
Preliminary data underline the fact that muscular deoxygenation during training happens earlier in adult patients suffering from neuromuscular disorders in comparison to controls, as it was demonstrated in Becker muscular dystrophy patients and fascioscapulo humeral muscular dystrophy. Moreover, the deoxygenation kinetics was positively correlated to the functional status and the muscular deficiency severity. However, no pediatric study has been conducted on this topic up to date.
The aim of the study is to determine if a correlation exists in children suffering from neuromuscular diseases:
6-17 years old patients suffering from neuromuscular disorder and able to walk
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
6 minutes walking test performed in the routine medical care with muscle oximetry recording in children suffering from neuromuscular diseases
Other: Muscular oximetry
6 minutes walking test performed in the routine medical care with muscle oximetry recording
Muscular oxygenation
Muscular oximetry
Time frame: 6 minutes
6 minutes walking distance
6 minutes walking distance
Time frame: 6 minutes
Motor function
Motor function measure (MFM scale)
Time frame: 25 minutes
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2018 to primary completion in May 2019, 14 months.
Of 64 non-industry observational studies under Neuromuscular Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 114. This study's 14 months is below that.
Counting every sponsor, half of 70 studies reached it within 37 months; a quarter within 12 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.